Rationale for Controlled Continuous Local Delivery of Sirolimus Through Porous ePTFE

• Sirolimus is an established FDA approved drug with a 20 year history of safety & efficacy

• Sirolimus formulation is stable at body temp

• Infusion can be adjusted, delayed or stopped

• Systemic drug concentrations of sirolimus well below immunosuppressive levels

• Ready antidote:  Stop or remove drug pump leaving a largely unaffected ePTFE graft